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Breast cancer is a heterogeneous disease, yet it remains 
possible to highlight common molecular signatures from 
distinct tumour subtypes. A frequent feature found in 
most breast cancer tumours is the constitutive activation 
of NF-κB, a family of transcription factors that play 
critical roles in cell survival, proliferation, inﬂ  ammation 
and immunity [1]. Deregulated NF-κB activation results 
in the persistent nuclear localization of proteins such as 
p50, p52, p65, cRel and RelB, which leads to the disrup-
tion of the balance between cell proliferation and death 
through the upregulation of anti-apoptotic proteins [2].
The main NF-κB-activating pathways
Two major NF-κB-activating pathways have been charac-
terized, referred to as the classical or canonical and the 
alternative or non-canonical pathways. Both rely on the 
signal-induced phosphorylation and degradation of an 
inhibitory molecule and the subsequent release and 
nuclear shuttling of NF-κB proteins. Yet, both pathways 
diﬀ  er by the signals that trigger them as well as by the 
identity of the activated kinases, the inhibitory molecule 
and the NF-κB proteins. Th   e classical pathway is typically 
triggered by pro-inﬂ  ammatory cytokines such as TNFα 
or IL-1β and ultimately leads to the degradation of the 
inhibitory molecule IκBα by the NF-κB essential modu-
lator (NEMO)/IκB kinase (IKK)γ-containing IKK com-
plex through a TAK1-dependent pathway [1] (Figure 1). 
Th   e p50/p65 heterodimer will then move into the nucleus 
to induce the expression of genes involved in cell 
prolifera  tion and survival, inﬂ   ammation and innate 
immunity. Th  e alternative pathway triggers the partial 
degradation of the inhibitory molecule p100 into p52 
through a NF-κB-inducing kinase (NIK)-dependent path-
way (Figure 1). Th  is cascade relies on an IKKα hetero-
dimer but not on NEMO/IKKγ and ultimately leads to 
the nuclear shutt  ling of p52/RelB dimers. Th  is  signalling 
pathway plays a critical role in adaptive immunity [1].
The classical NF-κB-activating pathway in breast 
cancer
Based on the key role of NF-κB in mammary epithelial 
proliferation, architecture and branching during early 
post-natal development [3,4], it was not surprising to see 
that the constitutive NF-κB activation found in several 
breast tumour cell lines has profound consequences in 
the initiation and progression of breast cancer [5]. NF-κB 
is mostly activated in oestrogen receptor-negative (ER-
negative) and ErbB2-positive tumours [6,7]. Importantly, 
a NEMO-binding domain (NBD) peptide, which acts as a 
selective inhibitor of the IKK complex, blocked heregulin-
mediated NF-κB activation and induced apoptosis prefer-
entially in proliferating cells, showing that the classical 
pathway largely contributes to tumour development [6]. 
Th   ose initial reports were followed by studies that more 
speciﬁ  cally addressed the role of NF-κB in breast tumour 
development in vivo. A genetic approach in which the 
classical NF-κB-activating path  way is inhibited in deﬁ  ned 
windows during polyoma middle T oncogene (PyVT) 
tumourigenesis showed that interfering with this pathway 
increases tumour latency and decreases tumour burden 
[8]. Th  ese ﬁ  ndings are in agreement with data showing 
the requirement of NF-κB for the induction and 
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© 2011 BioMed Central Ltdmaintenance of the epithelial-mesenchymal transition 
(EMT), a process that critically controls breast cancer 
pro  gression [9,10]. Indeed, the MCF10A immortalized 
cell line, which is derived from normal mammary 
epithelial cells, undergoes EMT when overexpressing the 
NF-κB protein p65. Th  is latter protein suppresses the 
expression of epithelial markers such as E-cadherin and 
desmoplakin but also induces the expres  sion of mesen-
chymal markers such as vimentin. Th  is process may 
occur through the NF-κB-dependent expression of 
ZEB-1/ZFHX1A and ZEB-2/ZFHX1B/Smad-interacting 
protein (SIP1), two transcriptional regulators known to 
Figure 1. The main NF-κB-activating pathways. On the left is the TNFα-dependent signalling pathway. The binding of TNFα to the TNF 
receptor TNFR1 triggers the sequential recruitment of the adaptors TRADD (TNFR1-associated death domain protein), RIP and TRAF2 (TNF 
receptor-associated factor 2) to the membrane. Then, TRAF2 mediates the recruitment of the IκB kinase (IKK) complex, composed of IKKα, IKKβ 
and NEMO (NF-kappa-B essential modulator), to the TNFR1 signalling complex. The scaff  old proteins TAB2 and TAB3 subsequently bind to Lys63-
polyubiquitylated substrates, such as receptor-interacting protein (RIP)1, resulting in TAK1 and then IKKβ activation. NEMO actually exerts its 
essential role in NF-κB activation by integrating upstream IKK-activating signals. Importantly, the linear ubiquitin (Ub) chain assembly complex 
(LUBAC), composed of two proteins, namely HOIL-1L (heme-oxidized IRP2 ubiquitin ligase-1) and HOIP (HOIL-1L interacting protein), binds 
NEMO in a TNFα-dependent manner, and generates and conjugates linear chains of ubiquitin on the scaff  old protein of the IKK complex [42]. 
The ubiquitin-binding motif of NEMO, referred to as the UBAN motif, is required to sense linear chains of ubiquitin. Activation of IKKβ leads to 
IκBα phosphorylation on specifi  c residues, polyubiquitylation through binding of ubiquitin proteins and its degradation through the proteasome 
pathway. Then, the heretodimer p50-p65 binds to specifi  c κB sites and activates a variety of NF-κB target genes coding for pro-infl  ammatory 
cytokines (IL-6) and chemokines. On the right is the alternative NF-κB-activating pathway. Binding of CD154 triggers the classical NEMO-dependent 
pathway (not illustrated) and the NEMO-independent cascade. This pathway relies on the recruitment of the heterodimer TRAF2-TRAF3 to the 
CD40 receptor. TRAF3 is required to connect the E3 ligases c-IAP1/2 (cellular inhibitor of apoptosis 1/2) to the kinase NIK (NF-κB-inducing kinase). 
NIK is activated by phosphorylation and is also subjected to a c-IAP1/2-dependent degradative polyubiquitination. IKKα homodimers are activated 
by NIK and phosphorylate the inhibitory molecule p100, the partial processing of which generates the NF-κB protein p52. This latter transcription 
factor moves into the nucleus as a heterodimer with RelB to regulate the expression of genes involved in lymphoid organogenesis or coding for 
chemokines (BLC (B lymphocyte chemokine)) or cytokines (BAFF (B-cell activating factor)).
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Th   ese data strongly suggest that NF-κB regulates breast 
tumour progression independently of its eﬀ   ects    on 
mammary development.
The alternative NF-κB-activating pathway in breast 
cancer
Th  e classical NF-κB-activating pathway is not the only 
one that contributes to breast cancer development. 
Indeed, early studies also demonstrated enhanced 
expression of the NF-κB protein p52 in breast cancer 
samples [11,12]. Moreover, increased p52/RelB activity 
was also observed in mouse mammary tumours induced 
by 7,12-dimethylbenz(a)anthracene (DMBA) [13]. Th  e 
deﬁ   nitive proof that the alternative NF-κB-activating 
pathway is involved in breast cancer development came 
from the phenotype of a mouse transgenic model in 
which p100/p52 is speciﬁ   cally overexpressed in the 
mammary epithelium by using the β-lactoglobulin milk 
protein promoter [14]. Th  is mouse model not only 
showed a delay in mammary development but also a 
transient reduction in ductal branching during preg-
nancy. Matrix metalloproteinase (Mmp)-2, Mmp-9 and 
cyclooxygenase (Cox)-2 turned out to be overexpressed 
in these transgenic mice. Constitutive p100 over  expres-
sion causes an aberrant phenotype, as shown by the 
thicken  ing of primary ducts, loss of epithelial cell organi-
zation and small areas of hyperplastic growth. Finally, an 
increase in p100/p52 expression was also observed in 
PyVT mice when tumour development is observed [14]. 
Importantly, no change of nuclear p65 was detected in 
this mouse model, suggesting that the phenotype 
observed was exclusively the result of a deregulated 
alternative NF-κB-activating pathway. Th   e expression of 
the NF-κB protein RelB, which is known to play a critical 
role in this signalling cascade, is increased in ERα-
negative breast cancer cells [15]. ERα actually represses 
NF-κB and AP-1 activities and consequently RelB expres-
sion. Interestingly, RelB is required for the maintenance 
of the mesenchymal phenotype of ERα-negative Hs578T 
breast cancer cells, at least in part through the trans-
criptional induction of BCL2 [15].
Other NF-κB-activating pathways in breast cancer
NF-κB is not exclusively activated through the TNF 
family of receptors. Indeed, the binding of epidermal 
growth factor (EGF) to its receptor (EGFR) also 
ultimately activates NF-κB and most likely contributes to 
the enhanced activity of this transcription factor in ER-
negative breast cancer cells [16]. Th   e exact mechanism by 
which EGF activates NF-κB in breast cancer cells remains 
unclear but may be similar to that described in lung 
cancer cells. EGF appears to trigger IκBα phosphorylation 
on tyrosine 42 through an IKK-independent pathway 
[17]. Of note, the inhibitory molecule ABIN-1 also 
negatively regulates EGF-mediated NF-κB activation, a 
pathway that requires its carboxy-terminal ubiquitin-
binding domain [18].
Th   e IKK complex is not the only one whose activation 
is often constitutive in breast cancer. Indeed, the so called 
IKK-related kinase IKKε is also overexpressed in some 
cases of breast adenocarcinomas as the result of the 1q32 
amplicon [19]. Th  is gene ampliﬁ  cation is not the only 
mechanism by which this kinase is aberrantly expressed, 
as more than 45% of IKKε-overexpressing breast 
carcinomas do not harbour the 1q32 amplicon. IKKε 
expression can be induced by casein kinase 2 (CK2) in 
breast cancer cells [20] and other pathways still to be 
characterized may also contribute to this phenomenon. 
Interestingly, this kinase is known to promote type I 
interferon gene induction through IRF3 phosphorylation, 
acts downstream of Akt and activates NF-κB by 
facilitating the nuclear localization of c-REL [19,20]. 
Importantly, all IKKε substrates identiﬁ   ed in breast 
cancer samples so far act as signalling molecules in 
NF-κB-dependent cascades and mediate the oncogenic 
potential of this IKK-related kinase. CYLD, a NF-κB 
inhibitor acting as a tumour suppressor, is phosphory-
lated by IKKε, a modiﬁ  cation that decreases its deubiqui-
tine ligase activity and consequently its inhibitory 
potential [21]. Th  erefore, an extensive understanding of 
the role of NF-κB in breast cancer development and 
progression should not be limited to the characterization 
of both classical and alternative pathways.
NF-κB and cancer stem cells
Self-renewing breast cancer stem cells are the subject of 
intensive research as key actors responsible for perpetu-
ating tumour existence and for treatment resistance and 
relapse. Th  ese cells can be isolated by virtue of their 
expression of the cell surface markers epithelial-speciﬁ  c 
antigen (ESA) and CD44 and the absence of expression of 
CD24. Th  e expression of aldehyde dehydrogenase has 
also been used to enrich for tumour-initiating cells and 
revealed that distinct breast cancers may contain cancer 
stem cells that harbour diﬀ   erent cell surface markers 
[22,23]. Importantly, stem cell properties can also be 
gained by transformed cells undergoing EMT [24].
At the molecular level, Wnt, Notch and Hedgehog 
developmental pathways control the self-renewal of 
normal stem cells and also appear to be deregulated in 
many human breast cancers [25]. Moreover, the 
membrane bound receptor tyrosine kinase Her2, which is 
overexpressed in 30% of breast cancers, also critically 
controls the cancer stem-cell population [26]. As Her2 
activates NF-κB through the canonical pathway [27], the 
hypothesis that this latter family of proteins may be 
involved in the biology of breast cancer stem cells made 
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model of Her2 breast tumourigenesis in which NF-κB 
was temporally suppressed in the mammary gland [28]. 
Th  is approach was elegant as NF-κB activation through 
the canonical pathway was only suppressed in mammary 
epithelial cells but not in inﬂ   ammatory cells, blood 
vessels or adipocytes, where this transcription factor 
most likely contributes to tumour development. More-
over, NF-κB suppression was inducible to circumvent the 
requirement of this transcription factor in normal ductal 
development. Th  e authors ﬁ   rst noticed that NF-κB is 
required for cell proliferation and colony formation of 
Her2-derived murine mammary tumour cell lines [28]. 
Th   ey subsequently observed that NF-κB governs the rate 
of initiation of Her2 tumours through multiple pathways 
ranging from reactive oxygen species production to 
cellular proliferation, invasion, inﬂ   ammation and vas-
culo  genesis. Mammary epithelial NF-κB contributed to 
the recruitment of tumour-associated macrophages. 
Interestingly, the proportion of CD44-positive cells 
dramati  cally decreased in Her2-dependent tumours 
where NF-κB was suppressed, thus indicating that this 
trans  cription factor maintains progenitor cell expansion 
[28]. Th  is result was further supported by the reduced 
formation of non-adherent mammospheres with cell 
lines derived from Her2-dependent tumours in which 
NF-κB was inhibited. Th  is phenomenon was potentially 
due to the reduced expression of key embryonic stem cell 
regulators such as Sox2 and Nanog [28]. As this study 
was based on the expression of an IκBα super repressor 
in which both serines 32 and 36 were mutated to 
alanines, the resulting phenotype was caused by a defec-
tive NF-κB and IKKβ-dependent activating path  way. Yet, 
this signal  ling cascade is not the only one that contributes 
to breast cancer stem cell expansion. Indeed, IKKαAA/AA 
knockin mice in which IKKα activation i  s disrupted by 
replace  ment of activation loop serines by alanines 
showed delayed tumour development when crossed with 
the Her2 murine breast cancer model [29]. Breast cancer 
cells from these mice generated primary but not 
secondary mammospheres, suggesting that IKKα is also 
required for the self-renewal of tumour-initiating cells 
from the Her2 breast cancer model.
IKKα appears to act as a central NF-κB-activating 
protein in the self-renewal of breast cancer stem cells, as 
evidenced by data obtained from additional mouse 
models of breast cancer. Indeed, deletion of IKKα in 
mammary-gland epithelial cells aﬀ   ects the onset of 
progestin-driven breast cancer [30]. Th   is kinase is 
actually activated through the Receptor activator of 
nuclear factor kappa-B ligand (RANKL)/RANK pathway 
when progesterone or synthetic derivatives (progestins) 
such as medroxyprogesterone acetate (MPA) are given in 
combination with the DNA-damaging agent DMBA to 
mice. As a result, cell proliferation occurs through cyclin 
D1  gene induction [30]. Interestingly, treatment with 
MPA alone led to a signiﬁ   cant expansion of luminal 
progenitor cells through a massive induction of RANKL, 
a phenomenon that was impaired in females defective for 
RANK. Mouse mammary tumour virus (MMTV)-RANK 
transgenic mice showed an enhanced susceptibility to 
mammary tumours following a MPA/DMBA treatment 
whereas RANK invalidation in the mammary gland 
resulted in a delayed onset and decreased incidence of 
progestin-driven breast cancers [30,31]. Importantly, 
breast cancer cells from MPA and DMBA-treated RANK-
defective mice formed primary but not secondary 
mammo  spheres, strongly suggesting that a loss of RANK 
expression markedly impairs the self-renewal capacity of 
cancer stem cells [30].
NF-κB appears to be activated during diﬀ  erentiation of 
the mammary colony-forming cells in which luminal 
progenitor cells can be found [32] (Figure  2). On the 
other hand, the mammary stem-like basally located cells, 
also known as mammary repopulating units, are devoid 
of NF-κB activity [32,33].
As a transcription factor required for the production of 
chemokines and cytokines, NF-κB has been deﬁ  ned as an 
essential actor in the link between inﬂ  ammation  and 
oncogenesis initiation and progression [34]. Indeed, 
inﬂ   ammatory molecules such as IL6 provide growth 
signals that promote malignant cell proliferation. 
Interestingly, a transient activation of the kinase onco-
protein Src in MCF10A cells results in phenotypic 
transformation that includes the formation of multiple 
foci, the ability to form colonies in soft agar and tumours 
in xenografts as well as mammosphere formation [35]. 
Th  is epigenetic switch, deﬁ  ned when a stable cell type 
changes into another stable cell type without any modiﬁ  -
cation in DNA sequences, involves a rapid inﬂ  ammation 
response that requires NF-κB [35]. More speciﬁ  cally, 
NF-κB activation triggers Lin28B expression, which in 
turn decreases Let-7 microRNA levels. As Let-7 micro-
RNA directly targets IL6 mRNAs by binding their 3’ un-
translated region, the IL6-dependent signalling pathways 
are strongly induced through the Src- and NF-κB-
dependent cascade [35]. Th  is newly deﬁ  ned  pathway 
appears to play a key role in the self-renewal capacity of 
breast cancer stem cells. Th  erefore, this study not only 
deﬁ  ned Src as an oncogenic kinase that promotes the 
expansion of breast cancer stem cells but also demon-
strated how critical NF-κB is in this process.
Unclear issues
Despite signiﬁ  cant progress in the elucidation of the roles 
played by NF-κB in breast cancer stem cell expansion, 
some issues remain to be experimentally addressed. Th  e 
gene candidates known to regulate embryonic stem cells 
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the mammary gland remain to be identiﬁ  ed. Are Sox2 
and Nanog induced by both IKKα and IKKβ? Cyclin D1, 
whose expression is strongly impaired in the IKKαAA/AA 
knockin mouse [4], may be one promising candidate as 
its kinase activity appears to be crucial for the self-
renewal of mammary stem and progenitor cells [36]. It 
also remains to be seen whether the alternative pathway 
is truly involved in breast cancer stem cell expansion. 
Based on the fact that the Her-2-dependent NF-κB 
activation pathway surprisingly relies on IKKα but not on 
IKKβ [27], the phenotype observed in the IKKαAA/AA 
knockin mouse crossed with the Her2 breast cancer 
model may actually be the result of a defective classical 
rather than alternative NF-κB activation cascade. In 
agreement with this hypothesis, the IKKαAA/AA mutation 
in mammary epithelial cells results in decreased nuclear 
levels of p50 and p65, the proteins acting in the classical 
pathway.
Most of the data showing a link between NF-κB and 
breast cancer stem cells were obtained using the Her-2 
tumour model, which classiﬁ  es with human luminal-type 
breast cancers. Th   e canonical NF-κB pathway is active in 
normal luminal progenitor cells and is consequently 
required for the formation of mammary epithelial 
tumours [32]. On the other hand, NF-κB appears to be 
dispensable for tumour development and progression in 
the MMTV-Wnt1 model, which classiﬁ  es with human 
basal-like breast cancers [29]. Th  is is most likely due to 
the absence of nuclear p65 in these lesions as well as in 
the mammary stem-like basally located cells, also 
referred to as mammary repopulating units [32]. Th  e 
molecular mechanisms underlying the speciﬁ  c  NF-κB 
activation in luminal progenitor cells remains to be 
elucidated. Th  e following years will provide further 
insights into the biology of both multipotent stem cells 
and lineage-committed progenitor cells and will tell us 
why and how NF-κB regulates their functions.
Th  e IKK-related kinase IKKε appears to act as an 
oncogenic protein through NF-κB, yet it is totally unclear 
whether and how this kinase promotes breast cancer 
stem cell expansion. Th  e generation of a new mouse 
Figure 2. Hypothetical model of the diff  erentiation hierarchy within the mammary epithelium and potential relationships with breast 
cancer subtypes. NF-κB activation through the canonical or the non-canonical pathway is depicted as p50/p65 or p52/RelB heterodimers, 
respectively. Cell surface markers used for the isolation of human epithelial cell subsets are shown in blue. Adapted from [32,33]. ER, oestrogen 
receptor; PR, progesterone receptor.
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useful to address this issue. Recent studies indicated that 
the IKK complex targets multiple substrates and there-
fore has additional NF-κB-independent functions in 
cancer [37]. Whether and how these unexpected roles 
contribute to breast cancer stem cell maintenance also 
remains an open question.
Important studies dedicated to the identiﬁ  cation of the 
cell of origin of solid tumours, including breast cancers, 
have been published [38]. Th   e cell of origin may corres-
pond to the normal tissue stem cell, which can take advan-
tage of its intrinsic self-renewal capacity. A restricted 
progenitor can, for other malignancies, act as the 
initiating cell, as reported, for example, for BRCA1-
associated breast cancers [39,40]. Breast cancers in the 
BRCA1  mutation carriers have a distinct basal-like 
phenotype, yet these tumours originated from luminal 
epithelial progenitors instead of from basal stem cells 
[39,40]. It remains to be seen whether and how NF-κB 
would be required for the conversion of a luminal 
progenitor cell to a basal gene expression proﬁ  le  in 
tumours originated in BRCA1 mutation carriers. Never-
theless, identiﬁ  cation of the cell origin is a key step to 
develop preventive therapeutic approaches in order to 
suppress or reverse the initial phase of the disease. In this 
context, the identiﬁ  cation of the RANKL/RANK/IKKα/
NF-κB axis as a key pathway that provides paracrine 
signals to stem cells means that it is conceivable to pre-
vent some cases of breast cancers by driving stem cells 
into a dormant state. Th   is strategy could be achieved by 
interfering with the RANK pathway with some speciﬁ  c 
inhibitors, some of which are already in clinical trials for 
bone metastasis [38].
An extensive knowledge of the biology of breast cancer 
stem cells is also crucial in order to better understand 
why some patients develop resis  tance to therapy such as 
Her2-targeting agents. Resistance to these drugs is the 
result of various somatic mutations that ultimately trigger 
aberrant phosphoinositide 3-kinase (PI3K)/Akt activation 
[41]. Although Akt appears to be dispensable for Her2-
mediated NF-κB activation in breast cancer cells [27], 
this transcription factor is nevertheless a key actor in 
chemoresistance. Future studies should also tell us 
whether and how NF-κB inhibition in breast cancer stem 
cells modulates their resistance to therapy.
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